A citation-based method for searching scientific literature

Anna Kotowska-Zimmer, Yuliya Ostrovska, Marta Olejniczak. Mol Ther Nucleic Acids 2020
Times Cited: 9







List of co-cited articles
120 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Shuming Ouyang, Yingjun Xie, Zeyu Xiong, Yi Yang, Yexing Xian, Zhanhui Ou, Bing Song, Yuchang Chen, Yuhuan Xie, Haoxian Li,[...]. Stem Cells Dev 2018
29
55

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice.
Lodewijk J A Toonen, Frank Rigo, Haico van Attikum, Willeke M C van Roon-Mom. Mol Ther Nucleic Acids 2017
55
55

Spinocerebellar ataxia.
Thomas Klockgether, Caterina Mariotti, Henry L Paulson. Nat Rev Dis Primers 2019
136
55

Spinocerebellar ataxias: prospects and challenges for therapy development.
Tetsuo Ashizawa, Gülin Öz, Henry L Paulson. Nat Rev Neurol 2018
80
55

Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Melvin M Evers, Hoang-Dai Tran, Ioannis Zalachoras, Barry A Pepers, Onno C Meijer, Johan T den Dunnen, Gert-Jan B van Ommen, Annemieke Aartsma-Rus, Willeke M C van Roon-Mom. Neurobiol Dis 2013
49
55

Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
Edgardo Rodríguez-Lebrón, Maria do Carmo Costa, Katiuska Luna-Cancalon, Therese M Peron, Svetlana Fischer, Ryan L Boudreau, Beverly L Davidson, Henry L Paulson. Mol Ther 2013
74
44

Pathogenesis of SCA3 and implications for other polyglutamine diseases.
Hayley S McLoughlin, Lauren R Moore, Henry L Paulson. Neurobiol Dis 2020
34
44

Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide.
Eleni Kourkouta, Rudie Weij, Anchel González-Barriga, Melissa Mulder, Ruurd Verheul, Sieto Bosgra, Bas Groenendaal, Jukka Puoliväli, Jussi Toivanen, Judith C T van Deutekom,[...]. Mol Ther Nucleic Acids 2019
19
44

Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease.
Maria do Carmo Costa, Katiuska Luna-Cancalon, Svetlana Fischer, Naila S Ashraf, Michelle Ouyang, Rahil M Dharia, Lucas Martin-Fishman, Yemen Yang, Vikram G Shakkottai, Beverly L Davidson,[...]. Mol Ther 2013
70
44

Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
Hayley S McLoughlin, Lauren R Moore, Ravi Chopra, Robert Komlo, Megan McKenzie, Kate G Blumenstein, Hien Zhao, Holly B Kordasiewicz, Vikram G Shakkottai, Henry L Paulson. Ann Neurol 2018
67
44

Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models.
Lauren R Moore, Gautam Rajpal, Ian T Dillingham, Maya Qutob, Kate G Blumenstein, Danielle Gattis, Gene Hung, Holly B Kordasiewicz, Henry L Paulson, Hayley S McLoughlin. Mol Ther Nucleic Acids 2017
66
44

CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo.
Alex Mas Monteys, Shauna A Ebanks, Megan S Keiser, Beverly L Davidson. Mol Ther 2017
141
44

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.
Daniel R Scoles, Pratap Meera, Matthew D Schneider, Sharan Paul, Warunee Dansithong, Karla P Figueroa, Gene Hung, Frank Rigo, C Frank Bennett, Thomas S Otis,[...]. Nature 2017
150
44

Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.
Jun Wan Shin, Kyung-Hee Kim, Michael J Chao, Ranjit S Atwal, Tammy Gillis, Marcy E MacDonald, James F Gusella, Jong-Min Lee. Hum Mol Genet 2016
123
44

Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias.
Ronald A M Buijsen, Lodewijk J A Toonen, Sarah L Gardiner, Willeke M C van Roon-Mom. Neurotherapeutics 2019
40
44

Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
Clévio Nóbrega, Isabel Nascimento-Ferreira, Isabel Onofre, David Albuquerque, Hirokazu Hirai, Nicole Déglon, Luís Pereira de Almeida. PLoS One 2013
82
33

Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease.
Isabel Nascimento-Ferreira, Tiago Santos-Ferreira, Lígia Sousa-Ferreira, Gwennaëlle Auregan, Isabel Onofre, Sandro Alves, Noëlle Dufour, Veronica F Colomer Gould, Arnulf Koeppen, Nicole Déglon,[...]. Brain 2011
128
33

Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease.
Isabel Nascimento-Ferreira, Clévio Nóbrega, Ana Vasconcelos-Ferreira, Isabel Onofre, David Albuquerque, Célia Aveleira, Hirokazu Hirai, Nicole Déglon, Luís Pereira de Almeida. Brain 2013
72
33

Targeting Huntingtin Expression in Patients with Huntington's Disease.
Sarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, Edward J Wild, Carsten Saft, Roger A Barker, Nick F Blair, David Craufurd, Josef Priller, Hugh Rickards,[...]. N Engl J Med 2019
249
33

Toward understanding Machado-Joseph disease.
Maria do Carmo Costa, Henry L Paulson. Prog Neurobiol 2012
158
33

Transplantation of cerebellar neural stem cells improves motor coordination and neuropathology in Machado-Joseph disease mice.
Liliana S Mendonça, Clévio Nóbrega, Hirokazu Hirai, Brian K Kaspar, Luís Pereira de Almeida. Brain 2015
54
33

Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype.
Mariana Conceição, Liliana Mendonça, Clévio Nóbrega, Célia Gomes, Pedro Costa, Hirokazu Hirai, João Nuno Moreira, Maria C Lima, N Manjunath, Luís Pereira de Almeida. Biomaterials 2016
54
33

Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease.
Sandro Alves, Isabel Nascimento-Ferreira, Gwennaëlle Auregan, Raymonde Hassig, Noëlle Dufour, Emmanuel Brouillet, Maria C Pedroso de Lima, Philippe Hantraye, Luís Pereira de Almeida, Nicole Déglon. PLoS One 2008
109
33

Silencing of genes responsible for polyQ diseases using chemically modified single-stranded siRNAs.
Agnieszka Fiszer, Marianna E Ellison-Klimontowicz, Wlodzimierz J Krzyzosiak. Acta Biochim Pol 2016
12
33

CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.
Su Yang, Renbao Chang, Huiming Yang, Ting Zhao, Yan Hong, Ha Eun Kong, Xiaobo Sun, Zhaohui Qin, Peng Jin, Shihua Li,[...]. J Clin Invest 2017
159
33

The Biology of Huntingtin.
Frédéric Saudou, Sandrine Humbert. Neuron 2016
349
33

Therapies targeting DNA and RNA in Huntington's disease.
Edward J Wild, Sarah J Tabrizi. Lancet Neurol 2017
133
33

Oligonucleotide-based strategies to combat polyglutamine diseases.
Agnieszka Fiszer, Wlodzimierz J Krzyzosiak. Nucleic Acids Res 2014
41
33

Mutant CAG Repeats Effectively Targeted by RNA Interference in SCA7 Cells.
Agnieszka Fiszer, Joanna P Wroblewska, Bartosz M Nowak, Wlodzimierz J Krzyzosiak. Genes (Basel) 2016
9
33

Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.
Holly B Kordasiewicz, Lisa M Stanek, Edward V Wancewicz, Curt Mazur, Melissa M McAlonis, Kimberly A Pytel, Jonathan W Artates, Andreas Weiss, Seng H Cheng, Lamya S Shihabuddin,[...]. Neuron 2012
454
33

Genome editing. The new frontier of genome engineering with CRISPR-Cas9.
Jennifer A Doudna, Emmanuelle Charpentier. Science 2014
33

Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.
Philipp Koch, Peter Breuer, Michael Peitz, Johannes Jungverdorben, Jaideep Kesavan, Daniel Poppe, Jonas Doerr, Julia Ladewig, Jerome Mertens, Thomas Tüting,[...]. Nature 2011
226
33

Polyglutamine spinocerebellar ataxias - from genes to potential treatments.
Henry L Paulson, Vikram G Shakkottai, H Brent Clark, Harry T Orr. Nat Rev Neurosci 2017
136
33

Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease.
Ana T Simões, Nélio Gonçalves, Arnulf Koeppen, Nicole Déglon, Sebastian Kügler, Carlos Bandeira Duarte, Luís Pereira de Almeida. Brain 2012
81
33

Spinocerebellar ataxia: an update.
Roisin Sullivan, Wai Yan Yau, Emer O'Connor, Henry Houlden. J Neurol 2019
59
33

Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features.
A Dürr, G Stevanin, G Cancel, C Duyckaerts, N Abbas, O Didierjean, H Chneiweiss, A Benomar, O Lyon-Caen, J Julien,[...]. Ann Neurol 1996
337
22

Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado-Joseph disease.
Joana Duarte-Neves, Nélio Gonçalves, Janete Cunha-Santos, Ana Teresa Simões, Wilfred F A den Dunnen, Hirokazu Hirai, Sebastian Kügler, Cláudia Cavadas, Luís Pereira de Almeida. Hum Mol Genet 2015
36
22

Loss of the Spinocerebellar Ataxia type 3 disease protein ATXN3 alters transcription of multiple signal transduction pathways.
Li Zeng, Dapeng Zhang, Hayley S McLoughlin, Annie J Zalon, L Aravind, Henry L Paulson. PLoS One 2018
12
22

Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8.
Melinda L Moseley, Tao Zu, Yoshio Ikeda, Wangcai Gao, Anne K Mosemiller, Randy S Daughters, Gang Chen, Marcy R Weatherspoon, H Brent Clark, Timothy J Ebner,[...]. Nat Genet 2006
305
22

CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1.
Y Kawaguchi, T Okamoto, M Taniwaki, M Aizawa, M Inoue, S Katayama, H Kawakami, S Nakamura, M Nishimura, I Akiguchi. Nat Genet 1994
22

Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia.
Clévio Nóbrega, Liliana Mendonça, Adriana Marcelo, Antonin Lamazière, Sandra Tomé, Gaetan Despres, Carlos A Matos, Fatich Mechmet, Dominique Langui, Wilfred den Dunnen,[...]. Acta Neuropathol 2019
20
22

Absence of ataxin-3 leads to cytoskeletal disorganization and increased cell death.
Ana-João Rodrigues, Maria do Carmo Costa, Teresa-Luísa Silva, Daniela Ferreira, Fernanda Bajanca, Elsa Logarinho, Patrícia Maciel. Biochim Biophys Acta 2010
29
22

Non-ATG-initiated translation directed by microsatellite expansions.
Tao Zu, Brian Gibbens, Noelle S Doty, Mário Gomes-Pereira, Aline Huguet, Matthew D Stone, Jamie Margolis, Mark Peterson, Todd W Markowski, Melissa A C Ingram,[...]. Proc Natl Acad Sci U S A 2011
539
22

Caloric restriction blocks neuropathology and motor deficits in Machado-Joseph disease mouse models through SIRT1 pathway.
Janete Cunha-Santos, Joana Duarte-Neves, Vitor Carmona, Leonard Guarente, Luís Pereira de Almeida, Cláudia Cavadas. Nat Commun 2016
59
22

Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy.
Carlos A Matos, Luís Pereira de Almeida, Clévio Nóbrega. J Neurochem 2019
42
22

From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
Jorge Diogo Da Silva, Andreia Teixeira-Castro, Patrícia Maciel. Neurotherapeutics 2019
16
22

Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3.
Sara Duarte-Silva, Andreia Neves-Carvalho, Carina Soares-Cunha, Joana M Silva, Andreia Teixeira-Castro, Rita Vieira, Anabela Silva-Fernandes, Patrícia Maciel. Mov Disord 2018
16
22

Re-establishing ataxin-2 downregulates translation of mutant ataxin-3 and alleviates Machado-Joseph disease.
Clévio Nóbrega, Sara Carmo-Silva, David Albuquerque, Ana Vasconcelos-Ferreira, Udaya-Geetha Vijayakumar, Liliana Mendonça, Hirokazu Hirai, Luís Pereira de Almeida. Brain 2015
24
22

Improvement in the molecular diagnosis of Machado-Joseph disease.
P Maciel, M C Costa, A Ferro, M Rousseau, C S Santos, C Gaspar, J Barros, G A Rouleau, P Coutinho, J Sequeiros. Arch Neurol 2001
93
22

RNA toxicity is a component of ataxin-3 degeneration in Drosophila.
Ling-Bo Li, Zhenming Yu, Xiuyin Teng, Nancy M Bonini. Nature 2008
220
22


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.